Dr. James Leon Khatcheressian, MD

Dr. Khatcheressian practices at Virginia Cancer Institute Incorporated in Richmond, Virginia.

Dr. Khatcheressian's NPI, 1366536674, was assigned on October 3, 2006. Dr. Khatcheressian graduated from Virginia Commonwealth University, School of Medicine in 1998. Dr. Khatcheressian holds Virginia license 0101102680.

Dr. Khatcheressian's primary practice is Virginia Cancer Institute Incorporated, at 7202 Glen Forest Dr, Richmond, VA 23226 in Henrico County. The practice phone is (804) 287-3000.

Dr. Khatcheressian's primary practice is Virginia Cancer Institute Incorporated in Richmond, Virginia. Dr. Khatcheressian is also affiliated with Bon Secours St. Mary's Hospital. The medical group on file is Virginia Cancer Institute. Dmand AI also links Dr. Khatcheressian to 3 more hospitals, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Khatcheressian practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Khatcheressian's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Khatcheressian is licensed in Virginia.

CMS data shows 40,772 Medicare services from Dr. Khatcheressian across 44 procedure codes in 2024, for 932 Medicare patients. Medicare paid $1,097,353 for them.

CMS counts 932 Medicare patients who saw Dr. Khatcheressian in 2024. The largest group is 65 to 74, with 416 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Khatcheressian's median patient age at 67, with 69% women.

In 2024, Dr. Khatcheressian wrote 2,133 Medicare Part D claims for 345 patients. 78% of them were for generic drugs. CMS names the drug for 1,914 of them, across 43 drugs with 11 or more claims each, at $3,526,236 in total drug cost. In 2023, CMS named 1,775 claims across 34 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Khatcheressian for performance year 2024, reported individually. Dr. Khatcheressian accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 8 papers to Dr. Khatcheressian, published from 2011 to 2016. 2016 was the busiest year, with 2. Dr. Khatcheressian's most frequent co-authors are Thomas J. Smith, MD, James O. Armitage, MD and Edward R. Arrowsmith, MD.

Dmand AI links Dr. Khatcheressian to 4 clinical trials, 3 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Breast Neoplasms, Lymphoma, Mantle-Cell and Multiple Endocrine Neoplasia Type 1. Novartis Pharmaceuticals sponsors the most, 2.

CMS Open Payments shows 92 general payments to Dr. Khatcheressian from 31 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 76% of the total. Daiichi Sankyo Inc. paid the most, $18,426. It also lists 2 research payments totaling $1,430 from 2016 to 2017.

Dr. Khatcheressian graduated from Virginia Commonwealth University, School of Medicine in 1998.